SCM
MRTX

Silverarc Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Silverarc Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200,000
Closed -$11.2M – 94
2023
Q3 		$8.71M Buy
200,000
+108,787
+119% +$3.88M 2.64% 9
2023
Q2 		$3.3M Buy
+91,213
New +$3.76M 1.02% 34
2022
Q4 		– Sell
-10,220
Closed -$714K – 105
2022
Q3 		$714K Sell
10,220
-26,183
-72% -$1.94M 0.24% 64
2022
Q2 		$2.44M Sell
36,403
-9,719
-21% -$618K 0.75% 37
2022
Q1 		$3.79M Sell
46,122
-14,635
-24% -$1.5M 1.57% 16
2021
Q4 		$8.91M Buy
60,757
+14,816
+32% +$2.3M 3.61% 7
2021
Q3 		$8.13M Buy
45,941
+8,188
+22% +$1.32M 4.59% 3
2021
Q2 		$6.1M Buy
37,753
+32,753
+655% +$5.26M 2.72% 5
2021
Q1 		$857K Sell
5,000
-15,000
-75% -$2.97M 0.47% 57
2020
Q4 		$4.39M Buy
+20,000
New +$4.32M 2.55% 11

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Silverarc Capital Management's MRTX Position: Q4 2023 in Review

Silverarc Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 200,000 shares — an estimated $11.2M sold.

Silverarc Capital Management first reported a position in MRTX in Q4 2020 and held it in 10 quarters. The position peaked at $8.91M in Q4 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Silverarc Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 200,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $11.2M.
  • Silverarc Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Silverarc Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $8.91M in Q4 2021.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.